Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation

NCT04781855 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped 0% Participants

Conditions

Hematopoietic and Lymphoid Cell Neoplasm
Recurrent Chronic Lymphocytic Leukemia
Recurrent Small Lymphocytic Lymphoma
Refractory Chronic Lymphocytic Leukemia
Refractory Small Lymphocytic Lymphoma
Richter Syndrome

Interventions

DRUG: Ibrutinib
BIOLOGICAL: Ipilimumab
BIOLOGICAL: Nivolumab

Sponsor

M.D. Anderson Cancer Center